IN8bio at Sidoti Small-Cap Virtual Conference: gamma-delta push

On 24 September 2026, small-cap firm IN8bio presented its two-pronged strategy to the Sidoti Small-Cap Virtual Conference, focusing on gamma-delta T cells for autoimmune disease and glioblastoma. The company showcased promising early data and a recent financing round, while also recognizing the need for further in vivo results, regulatory guidance, and increased investor confidence in the challenging cell therapy sector.

IN8bio's lead autoimmune program, INB-619, demonstrated strong in vitro B-cell killing without IL-6 secretion, a marker associated with cytokine release syndrome. The glioblastoma program has shown early clinical promise, with median progression-free survival improving from 6.6 months to 13 months and median overall survival increasing from 13.2 months to 19.5 months.

The company raised over $20 million in December 2025, with a potential second close of about $20 million to sustain operations through IND submission. Management highlighted several catalysts expected in 2026, such as first animal data for INB-619 and FDA guidance on the glioblastoma path forward.

IN8bio's co-founders, Will and Dr. Larry Lamb, are leveraging their extensive experience in biotech and cell therapy to develop therapies based on gamma-delta T cells, a less common immune cell type believed to offer a more precise and potent approach compared to CD3-based T cell engagers. The company's platform is positioned as a "scalpel" rather than a "sledgehammer," aiming for broader therapeutic windows.

They argue that gamma-delta T cells, which make up only 1% to 5% of immune cells, could be more potent due to their unique biology.